Dynavax Technologies Corp. [DVAX] stock prices are up 1.71% to $12.50 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DVAX shares have gain 6.84% over the last week, with a monthly amount drifted -1.96%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Dynavax to Present at TD Cowen’s 44th Annual Health Care Conference. In a post published today on Yahoo Finance, Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen’s 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET.
From an analyst’s perspective:
Dynavax Technologies Corp. [NASDAQ: DVAX] stock has seen the most recent analyst activity on February 01, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $20. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 27, 2022, and set its price target to $22. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $19 on August 06, 2021. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $12 on August 07, 2020. H.C. Wainwright reiterated a Buy rating for this stock on August 03, 2020, and upped its price target to $14. In a note dated June 15, 2020, Evercore ISI initiated an Outperform rating and provided a target price of $14 on this stock.
The stock price of Dynavax Technologies Corp. [DVAX] has been fluctuating between $9.48 and $15.15 over the past year. Dynavax Technologies Corp. [NASDAQ: DVAX] shares were valued at $12.50 at the most recent close of the market.
Analyzing the DVAX fundamentals
The Dynavax Technologies Corp. [NASDAQ:DVAX] reported sales of 232.28M for trailing twelve months, representing a drop of -69.87%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -0.11%, Pretax Profit Margin comes in at -0.02%, and Net Profit Margin reading is -0.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.01, Equity is -0.01 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.31 points at the first support level, and at 12.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.61, and for the 2nd resistance point, it is at 12.73.
Dynavax Technologies Corp. [DVAX] reported earnings per share of $0 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.01/share, meaning a difference of $0.01 and a surprise factor of 100.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.1 per share as compared to estimates of -$0.01 per share, a difference of $0.11 representing a surprise of 1,100.00%.
Ratios To Look Out For
It’s worth pointing out that Dynavax Technologies Corp. [NASDAQ:DVAX]’s Current Ratio is 13.81. As well, the Quick Ratio is 12.96, while the Cash Ratio is 2.42. Considering the valuation of this stock, the price to sales ratio is 7.03, the price to book ratio is 2.60.
Transactions by insiders
Recent insider trading involved Burgess Justin, Chief Accounting Officer, that happened on Mar 01 ’24 when 20526.0 shares were sold. SVP and CMO, Janssen Robert completed a deal on Jan 04 ’24 to sell 1500.0 shares. Meanwhile, President & COO Novack David F sold 9000.0 shares on Jan 02 ’24.
